サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1797270

上皮成長因子受容体-非小細胞肺がん（EGFR-NSCLC）の世界市場

Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC)

出版日
ページ情報
英文 283 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
上皮成長因子受容体-非小細胞肺がん（EGFR-NSCLC）の世界市場
出版日: 2025年08月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 283 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

上皮成長因子受容体-非小細胞肺がん（EGFR-NSCLC）の世界市場は2030年までに101億米ドルに達する見込み

2024年に75億米ドルと推定される上皮成長因子受容体-非小細胞肺がん（EGFR-NSCLC）の世界市場は、2024～2030年の分析期間にCAGR 5.2%で成長し、2030年には101億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるオシメルチニブは、CAGR 5.4%を記録し、分析期間終了時には45億米ドルに達すると予測されます。エルロチニブセグメントの成長率は、分析期間中CAGR 3.9%と推定されます。

米国市場は20億米ドルと推定、中国はCAGR 8.3％で成長予測

米国の上皮成長因子受容体-非小細胞肺がん（EGFR-NSCLC）市場は2024年に20億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.3%で推移し、2030年までに20億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.2％と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界のEGFR-非小細胞肺がん（NSCLC）市場- 主要動向と促進要因のまとめ

EGFRの状態はNSCLCの治療戦略にどのような影響を与えているか？

上皮成長因子受容体（EGFR）変異は、非小細胞肺がん（NSCLC）、特に腺がんサブタイプにおける重要なバイオマーカーです。これらの変異はEGFRシグナル伝達経路の過剰活性化につながり、制御不能な細胞分裂と腫瘍増殖を促進します。欧米の集団ではNSCLC患者の約10～15％、アジアの集団では最大40％がEGFR変異を示すため、個別化治療計画には分子検査が不可欠です。

EGFR変異の同定は、異常なEGFRシグナル伝達を阻害する標的療法、特にチロシンキナーゼ阻害剤（TKI）の使用を可能にしました。これらの薬剤は、従来の化学療法に比べて無増悪生存期間を改善し、毒性を軽減しています。ゲフィチニブやエルロチニブのような第一世代のTKIは、T790Mのような耐性変異を克服できるオシメルチニブのような新しい薬剤に取って代わられました。その結果、EGFR検査は現在、臨床腫瘍学のワークフローにおけるNSCLC診断の標準的な要素となっています。

どのような進歩が標的治療と耐性管理を再構築しているのか？

EGFR標的治療における最近の進歩は、薬剤選択性の向上、耐性の克服、副作用の最小化に焦点を当てています。オシメルチニブなどの第三世代TKIは、中枢神経系転移やそれ以前の治療に対する後天性耐性を有する患者において有効性を示しています。現在の薬剤では効果的に対処できない珍しいEGFR変異や複合変異を標的とした第4世代阻害剤の調査が進行中です。

リキッドバイオプシー技術は、EGFR変異の状態をモニターし、耐性変異をリアルタイムで検出する非侵襲的ツールとして台頭してきています。これらのツールはダイナミックな治療調整を可能にし、組織生検への依存を軽減します。TKIと抗血管新生剤、免疫チェックポイント阻害剤、または化学療法を含む併用療法も、奏効期間を延長し、生存期間を改善するために研究されています。このような治療法の革新は、特に再発・進行期のEGFR変異NSCLCの治療展望を広げつつあります。

市場需要に影響を与える患者集団とヘルスケアシステムは？

EGFR-NSCLCセグメントは、変異の有病率が高い東アジア諸国で特に重要です。これらの地域では、ルーチンの分子プロファイリングとEGFR阻害剤による早期治療が一般的な臨床慣行となっています。欧米のヘルスケアシステムでは、検査プロトコールが標準化され、償還政策によってサポートされるにつれて、採用が拡大しています。人口の高齢化、肺がん罹患率の上昇、ゲノム検査へのアクセスの増加は、世界的に適格患者の特定を増加させる一因となっています。

学術医療センターとがん治療病院は、研究試験、治療ガイドラインの更新、教育普及活動を通じて採用を導く中心的役割を担っています。遺伝子検査に対する患者の認識と精密腫瘍学に対する需要は高まっており、診断時点におけるEGFRスクリーニングをさらに促進しています。ヘルスケアシステムが価値に基づく治療を優先する中、バイオマーカー主導型治療へのシフトは、特に健康アウトカムとコスト効率が交差する分野で顕著になってきています。

EGFR-NSCLC市場の成長の原動力は何か？

EGFR-NSCLC市場の成長は、バイオマーカーの普及、薬剤の革新、精密腫瘍学の取り込みに関連するいくつかの要因によってもたらされます。特定の集団におけるEGFR変異の高い割合が、広範な検査と標的治療の採用を支えています。耐性および中枢神経系を侵す疾患に対する有効性が改善された次世代TKIの開発により、治療期間が拡大し、患者の転帰が改善されています。

コンパニオン診断薬の統合とゲノム検査に対する償還支援により、標的化可能な変異の早期同定が強化されています。新規EGFR阻害剤の臨床試験の拡大と規制当局の承認により、特にこれまで十分な治療が行われていなかった患者サブセットにおける治療の選択肢が増加しています。個別化医療と標的治療の臨床的価値に対する認識の高まりは、医師の採用とシステムレベルの統合を強化しています。これらの要因が総合的に、EGFR-NSCLC治療市場への持続的な投資と治療の進歩を促しています。

セグメント

薬剤タイプ（オシメルチニブ、エルロチニブ、アファチニブ、ゲフィチニブ、ダコミチニブ）、流通チャネル（オフライン、オンライン）

調査対象企業の例

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen（Black Diamond Therapeutics）
  • Blueprint Medicines Corp.
  • Boehringer Ingelheim
  • Cullinan Therapeutics
  • Daiichi Sankyo Co., Ltd.
  • Dizal Pharmaceutical
  • Eli Lilly and Company
  • Genentech（Roche Group）
  • Merck & Co., Inc.
  • Mirati Therapeutics
  • Novartis AG
  • Oric Pharmaceuticals
  • Pfizer Inc.
  • Roche（F. Hoffmann-La Roche Ltd.）
  • Takeda Pharmaceutical Company Ltd.
  • Taiho Pharmaceutical Co., Ltd.
  • Zai Lab

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38790

Global Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market to Reach US$10.1 Billion by 2030

The global market for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) estimated at US$7.5 Billion in the year 2024, is expected to reach US$10.1 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Osimertinib, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Erlotinib segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 8.3% CAGR

The Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global EGFR - Non-Small Cell Lung Cancer (NSCLC) Market - Key Trends & Drivers Summarized

How Is EGFR Status Influencing Treatment Strategies in NSCLC?

Epidermal Growth Factor Receptor (EGFR) mutations are a key biomarker in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma subtypes. These mutations lead to overactivation of EGFR signaling pathways, promoting uncontrolled cell division and tumor growth. Approximately 10-15% of NSCLC patients in Western populations and up to 40% in Asian populations exhibit EGFR mutations, making molecular testing critical for personalized treatment planning.

Identification of EGFR mutations has enabled the use of targeted therapies, notably tyrosine kinase inhibitors (TKIs), which inhibit aberrant EGFR signaling. These drugs have improved progression-free survival and reduced toxicity compared to conventional chemotherapy. First-generation TKIs such as gefitinib and erlotinib have given way to newer agents like osimertinib, which can overcome resistance mutations such as T790M. As a result, EGFR testing is now a standard component of NSCLC diagnosis in clinical oncology workflows.

What Advancements Are Reshaping Targeted Therapy and Resistance Management?

Recent advancements in EGFR-targeted therapy focus on enhancing drug selectivity, overcoming resistance, and minimizing adverse effects. Third-generation TKIs such as osimertinib have shown efficacy in central nervous system metastases and in patients with acquired resistance to earlier therapies. Research is ongoing into fourth-generation inhibitors designed to target uncommon EGFR mutations or compound mutations that current drugs cannot address effectively.

Liquid biopsy technologies are emerging as non-invasive tools to monitor EGFR mutation status and detect resistance mutations in real time. These tools enable dynamic treatment adjustment and reduce reliance on tissue biopsy. Combination therapies involving TKIs and anti-angiogenic agents, immune checkpoint inhibitors, or chemotherapy are also being studied to prolong response duration and improve survival. These therapeutic innovations are expanding the treatment landscape for EGFR-mutated NSCLC, particularly in relapsed and advanced-stage patients.

Which Patient Populations and Healthcare Systems Are Impacting Market Demand?

The EGFR-NSCLC segment is especially significant in East Asian countries where mutation prevalence is high. In these regions, routine molecular profiling and early-stage treatment with EGFR inhibitors are common clinical practices. In Western healthcare systems, adoption is growing as testing protocols become standardized and supported by reimbursement policies. Aging populations, rising lung cancer incidence, and growing access to genomic testing are contributing to increased identification of eligible patients globally.

Academic medical centers and cancer treatment hospitals play a central role in guiding adoption through research trials, updated treatment guidelines, and educational outreach. Patient awareness of genetic testing and demand for precision oncology is increasing, further promoting EGFR screening at the point of diagnosis. As healthcare systems prioritize value-based care, the shift toward biomarker-driven treatment is becoming more prominent, especially where health outcomes and cost efficiency intersect.

What Is Driving Growth in the EGFR - NSCLC Market?

Growth in the EGFR-NSCLC market is driven by several factors related to biomarker prevalence, drug innovation, and precision oncology uptake. High rates of EGFR mutations in specific populations are supporting broad testing and targeted therapy adoption. Development of next-generation TKIs with improved efficacy against resistant and CNS-involved disease is expanding treatment duration and improving patient outcomes.

Integration of companion diagnostics and reimbursement support for genomic testing are enhancing early identification of targetable mutations. Expansion of clinical trials and regulatory approvals for novel EGFR inhibitors are increasing treatment options, especially in previously under-addressed patient subsets. Rising awareness of personalized medicine and the clinical value of targeted therapies is strengthening physician adoption and system-level integration. These factors are collectively driving sustained investment and therapeutic advancement in the EGFR-NSCLC treatment market.

SCOPE OF STUDY:

The report analyzes the Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Osimertinib, Erlotinib, Afatinib, Gefitinib, Dacomitinib); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen? (Black Diamond Therapeutics)
  • Blueprint Medicines Corp.
  • Boehringer Ingelheim
  • Cullinan Therapeutics
  • Daiichi Sankyo Co., Ltd.
  • Dizal Pharmaceutical
  • Eli Lilly and Company
  • Genentech (Roche Group)
  • Merck & Co., Inc.
  • Mirati Therapeutics
  • Novartis AG
  • Oric Pharmaceuticals
  • Pfizer Inc.
  • Roche (F. Hoffmann-La Roche Ltd.)
  • Takeda Pharmaceutical Company Ltd.
  • Taiho Pharmaceutical Co., Ltd.
  • Zai Lab

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of NSCLC Globally Drives Sustained Demand for EGFR-Targeted Therapeutics
    • Increased Adoption of Precision Oncology Approaches Strengthens Business Case for EGFR Mutation Testing and Targeted Therapy
    • Advancements in Liquid Biopsy Technologies Accelerate Non-Invasive Detection of EGFR Mutations
    • Expanding Role of Companion Diagnostics Throws Spotlight on Personalized EGFR Therapy Regimens
    • Regulatory Approvals for Next-Generation EGFR Inhibitors Propel Growth in First-Line and Refractory NSCLC Treatment
    • Growing Use of Osimertinib and Other Third-Generation TKIs Spurs Shift in Standard of Care for EGFR-Positive Patients
    • Emerging Resistance Mutations in EGFR Pathways Generate Opportunities for Combination and Sequential Therapy Approaches
    • Expansion of Molecular Testing Programs in Emerging Markets Enhances EGFR Mutation Identification and Drug Uptake
    • Increasing Enrollment in Clinical Trials for Novel EGFR Agents Sustains Innovation Momentum Across Therapeutic Classes
    • Integration of AI in Biomarker Discovery Enhances Targeted Drug Development for EGFR Subtypes in NSCLC
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Osimertinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Osimertinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Osimertinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Erlotinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Erlotinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Erlotinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Afatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Afatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Afatinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gefitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gefitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Gefitinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dacomitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dacomitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Dacomitinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION